Prenetics Global Limited (PRE) Earnings Call Transcript
August 18, 2026
Earnings Call Speaker Segments
Thanks, Shannon. Morning, everybody. First off, I really appreciate all of you taking the time to join. This marks the very first time in the history of our company that we've held a live earnings video webcast. Judging by the figures on the people logging in at this moment, it could be the biggest gathering of our shareholders that has ever occurred in a single spot. So if you're running a fund, if you own just one share, or if you're here simply because you drink the sachet each morning, we're glad to have you. This is meant for you. Let me explain the reasoning behind this format. The people who own our stock stretch all the way from worldwide institutions to individuals who came across IM8 as customers and then turned into shareholders. In our view, all of them are entitled to information of equal depth at the very same time. Right now, we've made the book available to everybody simultaneously. There's a straightforward reason we're able to do that. At this point we possess 20 months of data, covering each cohort, each month, each market, tracked from beginning to end. That's sufficient history that the figures no longer require adjectives from me. Let me put it bluntly: I'm not aware of any other business, whether it trades publicly or stays private, that has revealed its operations at the degree of detail we're presenting to you right now. I've just put out a 40-page shareholder letter, and it was composed to be read properly rather than skimmed. There's also an 80-page investor deck on top of that, which displays this business the way I view it from inside. Each cohort, each vintage, our complete acquisition cost broken out month by month, plus even independent cart data that benchmarks our retention against every brand in our category. During this stream, you'll be hearing directly from us. At the conclusion of this call, please feel free to ask whatever you'd like. A business growing this quickly ought to be scrutinized, not boiled down. When the figures look this strong, transparency becomes a weapon. On the day those figures get softer, at some point you'll hear about it from us first, in that letter. There's one commitment I want to make during this next half hour: I won't be standing up here merely reading that letter aloud to you. Still, my hope is that everyone listening can go through it later today. What I owe you is the portion of the document that can't capture the story of what really took place, how a brand that didn't exist two Decembers ago crossed a threshold last month that the vast majority of consumer companies never get to; but before I get into even one number, I want to first show all of you what we're building. We put this video together, two minutes long. Enjoy.
Prenetics owns IM8. Give us a bit of background on what IM8 actually is. This is a supplement we came up with. We make nutrition straightforward. Everything you need is packed into a single sachet with IM8. How far are you prepared to go to become the greatest? When it comes to the businesses we enter, we are extremely deliberate. I'm not sure if any of you are familiar with IM8, but you ought to buy IM8 since it contains 92 ingredients. Is that what makes you so successful, IM8? IM8 is my secret. There's no need to swallow 15 or 18 pills each morning. It's simply convenient, and it's incredibly beneficial for you and for how long you live. Every morning I eagerly anticipate this; in fact, it motivates me to consume more liquids, because I don't truly like drinking them unless I've stirred that IM8 into them. From the very first time I used IM8, wow, I've felt fantastic. IM8 provides me with the resistance and vitality to get up each morning, feel great, and do well. For me, I think it isn't just that my physician suggested it — I'm aware that IM8 has conducted a great deal of scientific study, which gives me confidence that with IM8 I'm in very trustworthy hands. Well, to start with, this man first told me about the brand. You're welcome. It's a fantastic product; it genuinely delivers results. That's the reason I pick IM8; so thanks to this $1 billion growth financing, we can now test far more, move into additional channels, try out fresh creatives, and experiment with new offline activations and partnerships. This growth financing isn't only about acquisition — it's truly for anything tied to the brand and to marketing. The finest pick the finest.
Okay, so that has really been a standout across the past 20 months, and what we've managed to accomplish is pretty remarkable, isn't it? Brian, let's move to the following slide. IM8 came to market in December 2024. During that initial month of sales, we generated roughly $400,000; and I'd like to share what our belief was at that time, since we wrote it down. It existed at the moment we founded the company, before even one sachet had been shipped. Our belief was that if we created the finest product available in this category — clinically studied, certified — customers wouldn't merely purchase it, they would remain. And should they remain, each dollar we invested in acquiring them would return to us with profit added. And if that proved true, eventually the entire operation would pass a threshold, the moment when expansion no longer burns cash but begins generating it. That threshold was marked in our model from day one. Each choice we've made has aimed toward it. Last month, we passed it. During July, our consolidated adjusted free cash flow — and I want to be exact here, since exactness is the entire purpose of today — that metric accounts for the funding under our General Catalyst facility, and it went positive for the very first time in company history; in my view, that stands as the most significant single fact in the letter, in the deck, and in this stream. And honestly speaking, I didn't think we'd reach it this quickly. Twenty months — most consumer brands require years. A great many never get there at all. Two factors enabled this, and they're linked. First, our cohorts led the way — customers who remained, who spent increasingly, who recovered their acquisition expenses within months. Those cohorts then unlocked a second factor: $1 billion of commitment from General Catalyst, made after they'd spent months examining our data, capital that now finances our expansion, meaning our own cash doesn't have to; we anticipate Q3 will be our first profitable quarter, and we anticipate remaining profitable afterward. Now, on to the quarter itself. Just underscoring what we've managed to deliver in Q2, and I want to present it the sole way results ought to be presented — relative to what we promised you and what we said we'd do previously; so back in May, we publicly guided to $46 million-$48 million in total revenue, $44 million-$46 million for IM8; those figures were reaffirmed in June; this morning, we reported $46.5 million total, up 29% versus Q1, approximately 3.9x compared with a year earlier, with IM8 contributing $45 million, rising 33% sequentially at 65% gross margins. Both figures landed within both ranges. Our sixth straight record quarter. We state what we'll do, and then when we deliver, I want to acknowledge that pattern before all of you. For the record, because that's the standard you ought to hold us to each quarter going forward. Then July arrived. Looking at this chart, it lays out the journey we took from December 2024 all the way through July, which was last month. We begin at that $400,000 figure I mentioned to you, and then check out where it finishes. In the last month, we brought in $20.9 million of revenue during a single month — the strongest month we have ever had, which is 4.3x what we did last July, working out to an annualized run rate of approximately $251 million. July wasn't merely large. It gave us the biggest single-month customer cohort in our history. A total of 47,373 customers came on board. Now here's what makes me proudest. That record cohort was acquired at a customer acquisition cost of roughly $239, which is down about 21% from our Q2; record customers alongside falling CAC — scaling brands never achieve both at once. Brian, in a few minutes, is going to break down the entire P&L in a few minutes and walk through every detail on that. The quarter came in within our own guidance, and with a July like that behind us. What I can promise going forward is change. Today, for the first time, we are also lifting our full year total revenue guidance to $220 million-$230 million, with IM8 contributing $215 million-$222 million. Grasp what that number really means. The bottom end of that range isn't wishful thinking; it's genuinely backed by subscribers we already have. We're also introducing something else today, the 2027 figures. As we approach the end of 2026, 2027, we are initiating $400 million or more. There are three numbers you should be considering right now, because they contain the entire story of this company. Last year, our first full year of IM8, we reached $60 million; in our second year, this year, we will reach $220 million. $400 + million expected in its third year. In the letter, we framed it one way, but we will tell you plainly. That trajectory is not something we treat as ambition, we treat it as arithmetic. We will exit this year above a $300 million run rate before even a single 2027 customer walks through the door. Keep in mind that roughly 87% of our revenue is recurring, from subscribers we already have. Our retention curves have been measured across 20 consecutive cohorts, all behaving identically. Nothing from the new products you'll hear about today is included in any of those numbers. Every launch is pure upside to every figure I just gave you — that is the promise. Now let me show you the machine underneath it. I want to spend a few minutes talking about the brand we are building, because, again, in my experience as an entrepreneur, as an investor, I have never seen anything like this, I am so grateful to live this every single day; this is something numbers cannot capture, something you can only see with your own eyes. As you may know, I spend much of the year traveling across the entire world for IM8; in every country I land in, the same thing always happens. When it comes to IM8, folks walk up to me and they're beaming, and that's not due to them knowing my face. What they're recognizing is their own sachet. Athletes, surgeons, founders, CEOs, high performers — individuals who could afford to purchase whatever they want — come to me without any prompting and describe what this product has done in their lives. Since we've been in existence, we've now held over 100 brand events across the globe, and each room is more packed than before. Dave and I discuss this constantly, since it's what fills us with the most pride. At some point during the past 20 months, this went from being a product that people purchase to something they keep with them, ask one another about, and pass along to those they love most. I'm able to say this on an earnings call for a solid business reason: a brand that people trust spreads. It reaches new countries before our marketing does, which explains why our acquisition cost is dropping even as our spend has doubled in Q2, and it reaches new products where an audience already convinced by us awaits whatever we create next. The pipeline as it currently stands, and once more, the brand we've managed to build and where we're going next, correct?
Since what you've witnessed so far is basically a single-product family within a single category. In Q4, the upcoming quarter, we will bring IM8 hydration to market in a space worth $37 billion. During next year's first quarter, our premium gummy range enters a $25 billion category, and no product ships absent clinical validation at the IM8 standard. Every item we produce holds NSF Certified for Sport; regarding the science supporting it, three randomized placebo-controlled clinical trials are running at this very moment, among them one at the Mayo Clinic, and Dr. Dawn Mussallem will walk you through those trials before long. I'll put it this way: within a category where marketing claims are the foundation, ours rests on evidence. Now, I also want each of you to grasp that although hydration gummies arrive next, that isn't the entire picture. Since I believe the brand we've managed to build can accomplish far more. Take a look at the slide shown here. We're discussing, once again, sleep, cognition, recovery, women's health, men's health, sports performance. Whenever a customer gives our sachet to a person they care about, they're signaling that we'll be trusted in whatever category gets decided by science and quality, and that map covers the majority of consumer health. Let me be just as clear regarding what this slide isn't. It isn't a roadmap. Nothing is being announced by me today. Still, the truthful way to regard IM8 isn't merely as a supplement company; it's a trusted global premium health brand, 20 months old, with the bulk of its categories still in front of it. Here's the question every operator listening already has. Moving into new categories typically demands armies, fresh teams, added overhead, margin heading out the exit. Allow me to demonstrate why such math doesn't hold for us. This chart depicts our AI native organization, and alongside the adjusted cash flow slide it might be my favorite in the deck. From day one, IM8 has been an AI native organization. We're approximately 70 people producing this year's guided $220 million-$230 million in revenue. That's more revenue per employee than any scaled brand in this category, and the gap widens as we grow. Revenue rose 3.9 x year-over-year without hiring rising proportionally. Fixed operating expenses in fact dropped 21% quarter-over-quarter. We doubled acquisition spend between Q1 and Q2 while team numbers stayed the same; that isn't discipline for its own sake; it's what a company looks like when AI runs through creative marketing operations finance from day one, instead of being bolted on later. Most companies our size are hiring their way to scale. We are compounding our way there. This year's biggest partnership is the one funding everything I just described. One month ago, General Catalyst committed $1 billion against our cohorts. The deepest diligence I've been through as a founder, every single monthly cohort examined at a transaction level. So, to take you through what that figure looks like right now, I'll pass things over to Brian, our CFO. Brian came aboard just 3 months back, once that diligence process had already gotten underway. Let me put it bluntly: adding Brian to the team ranks among the strongest calls we've made in this year. He showed up to inspect the machine, and he chose to stick around and crunch its numbers. Brian, over to you.
Okay, thank you, Danny, and I appreciate that introduction. Before we dive into this quarter, I want to say a brief word about myself, because for some of you, this may be the first occasion you're hearing my voice or seeing my face. I've spent a very long time serving as a CFO within the consumer packaged goods industry. IM8 actually marks the eighth brand I've had the chance to be involved with in this sector or in closely related ones. When the chance to come aboard this company first came my way, I responded the way any competent CFO would. I ran diligence on it and sized it up using essentially the same yardsticks we'll be examining here today. You examine what's behind you, what's in front of you right now, and what lies ahead. You begin with the financial statements, which provide a solid read on how the company has done historically and the short-term patterns that brought it to where it stands at that moment. Honestly, whatever the most recently reported quarter happens to be, it's already somewhat dated by nature, yet those quarters also reflect the outcome of considerable operational work put in during the preceding few quarters. Reading a financial statement tends to feel like gazing into the rearview mirror. Then, shifting to the current picture, I frame it in terms of cohort math along with unit economics. Examining those metrics lets you forecast with reasonable confidence where a brand is headed over the next, say, 3 to 6 quarters. There's fairly solid visibility into how much growth the company is pursuing. It further reveals, at the level of unit economics, the areas where the company is able to scale and the openings through which it can accomplish that. Those are consistently the things I turn to afterward. Third, when your gaze moves toward what's coming, that centers more on avenues for expansion, the value of the brand, its underlying strength, and pinpointing where openings exist across product, market, and channel. Where is the brand capable of reaching, and in which arenas can it compete? As I carried out this evaluation of IM8, every successive piece made me more optimistic than the one before. The financials came in strong, the unit economics plus cohort math proved quite robust, and regarding the future, clearly, given Danny's vision, there's no ceiling for this company. Today I'll walk us through that same kind of arc regarding the. We're going to examine the unit economics and cohort math underlying the recent quarters, which will provide us solid visibility into what's ahead in the shape of our near-term guidance; after that I'll hand things to Danny to discuss the future further, though I'll briefly address how that future is supported through a strong balance sheet along with today's General Catalyst financing partnership. With all that said, let's turn to the quarter. I want to take a good chunk of time here to walk through the P&L, since it's genuinely crucial that everybody gets aligned on how this view is presented and what we're going to hold ourselves accountable to going forward. Turning to the quarter — Q2, so roughly the center column on this chart — revenue came in at $46.5 million, up 29% versus the prior quarter and 3.9 x larger than the same time last year. From there we get to gross profit, which was $30.2 million at a 65% gross margin — roughly 3 full points above where it stood in the comparable period a year ago. Fixed operating costs totaled $8.8 million, equal to 19% of sales. Keep in mind that's a 14% increase from the previous quarter, yet 2.3 x what it was a year ago. As you'd anticipate, there's substantial additional leverage coming off that line. Danny brought up how AI-native this business is. Naturally, as a company scales, you'd expect operating cost measured against sales to keep shrinking — and that carries us to contribution profit. Plenty of brands calculate contribution somewhat differently. I've watched numerous brands show contribution profit ahead of G&A, ahead of operating expenses, and I've never believed that's a particularly useful approach, because once you truly think it through, operating costs are precisely what's needed to run the business as it stands today. Those costs support the existing customer base, existing ad spend, the current marketing team, and simply the everyday functioning of the present. To me, contribution profit amounts to gross profit less operating cost, with whatever remains as contribution profit and contribution margin as a share of revenue prior to making deliberate investments in demand creation and customer acquisition. You'll then see, beneath contribution profit — $21.4 million for the quarter, or 46% of sales — a margin that's 16% stronger than what we recorded a year earlier. Considerable leverage has materialized at that contribution profit line, which, once again, will be a metric that really matters to watch going forward. Underneath that sits what we call our demand creation bucket — essentially our all-in marketing. We've broken it into three separate lines. For a brand such as ours, most companies simply report marketing as a single figure. We've chosen to go a bit deeper and reveal how much goes to brand royalty, how much to ambassador partnerships, and how much sits in the paid acquisition marketing spend bucket alone. That acquisition marketing spend reached $36.2 million this quarter, representing 78% of sales — this is the numerator in what we'd call our CAC equation. Any time we discuss CAC, this is the numerator. Brand royalty for us generally runs at 3.5% of revenue; that's the contracted royalty tied to the business. You'll see that our ambassador contracts came to $2.1 million for the quarter, which works out to 4% of revenue, compared with $1.1 million in the ambassador line last year, when it was 9% of revenue. This line covers every ambassador partnership we have — our equity athletes, our lifestyle ambassadors, and our scientific advisory board too. That's what goes into it. If you look at marketing as a whole, for us it's really a dial controlling how much profit we throw off today versus how much growth we build for tomorrow. Each acquisition dollar we've spent has returned $1.52 of gross profit across the life cycle of our business, and that figure took in a number of cohorts that aren't all that mature yet; for every dollar spent, $1.52 of gross profit has come back to us. That straight return — we'll dig into the unit economics shortly — but this spending is genuinely our call about whether to drive profit today or growth for tomorrow. Our adjusted EBITDA of — $19 million for the quarter is really just a byproduct of our marketing spend which, as Danny mentioned, we doubled versus the prior quarter, even though our CACs have actually come down. Below adjusted EBITDA, we have adjustments for fair value gains of $9.9 million in the quarter.
When you add back depreciation and amortization, you land at a net loss of $9 million for the quarter, which works out to $0.52 a share. Compared with the same period a year earlier, when our loss per share came in at $0.94, that marks a 45% decline — in many respects, a fantastic quarter. Finally on this slide, there's the July column where Danny presented July revenue. July was an outstanding month for us, so we thought it prudent to share what the preliminary results for July look like, since this business has strengthened materially in a manner that's pretty thrilling as we move into Q3 and the remainder of this year. For Prenetics overall, revenue reached $21.4 million. For IM8, it was slightly below that, as we'll see shortly. Gross margin came in at 64% on that. Our operating costs fell to 15% of revenue, down from 19% only last quarter, so there's some solid expansion there. Contribution profit was $10.4 million for the month alone, a 49% contribution margin. Our spend, as you'll notice, actually declined relative to the Q2 average. That wasn't really a deliberate choice. We brought in far more new customers during the quarter, meaning our CACs improved so dramatically that our marketing line — or rather our acquisition marketing line — as a percentage of sales fell to 54%, leaving our adjusted EBITDA for July at a $2.4 million loss, or an adjusted EBITDA margin of just 11%. Bringing that down, net loss was a $3.6 million loss for July alone. As you can see, July is laying the groundwork for a genuinely strong Q3. Next we'll take a quick look at the IM8-specific segment, or business unit rather. Same P&L view. IM8 is essentially all of Prenetics today. Going forward, as we report, we won't necessarily break out IM8 separately from total Prenetics, since there's really not much need to. But here's the same P&L view for Q2 on IM8: $45 million of revenue, so nearly all of it, all the way down to the EBITDA line, which is an $18.6 million loss for the period. Marketing was almost entirely IM8's. What you're looking at is a P&L quite similar to Prenetics, but now check the bottom chart. This is what we were referring to with the customer acquisition metrics. You can see 118,000 new customers were acquired during the quarter; that's 98% better than the prior quarter. So let that sink in. 98% better on the quarter, and our CACs were flat to slightly down at 1%. You don't often see a business manage to double its spend while its customer acquisition efficiency improves slightly or even stays flat. If you go a step further and check the July column, all the way down at the bottom right, you'll notice we added 47,000 new customers in July, which Danny brought up, at a CAC of $239. That works out to a CAC that's 21% lower than the average Q2 figure, and versus July it got better by 20%. Over 20% growth in customers, 21% better CAC. Those two items are trending in a direction we haven't yet built into our future models; when we model the business, we use a CAC that's more consistent with what we saw during the first half. Naturally, we'd like to see our CAC efficiency keep going. Everything looks strong, but we haven't really gone back and changed any of our guidance to bake in that kind of CAC gain from July. It's simply the business scaling. We'll turn to the remaining financial statements as a sort of wrap-up of the past, as we're calling it, for the financials. Now looking at the cash flow perspective. The first half really tells the tale of two big investments. The loss for the period, as we observed, was driven entirely by customer acquisition spending for future growth — that's the first big investment in the first half. So the operating loss came in at $27 million; beyond that, we then carried out a share buyback of $40 million, which represented a $36.1 million cash outlay by us, net of proceeds, as your second big investment. You can see both of those lines bring you to roughly $27 million on the operating loss side, and then $36 million on the buyback net of proceeds. What will shift going forward is that General Catalyst funding is going to cover 70% of that acquisition marketing line. Our largest line in our P&L is now 70% funded as it comes in. Net of our repayments to them, that will still produce a fair amount of adjusted free cash flow positive momentum in future quarters, beginning with the month of July. Let's take a quick look at the balance sheet now; we have a very strong balance sheet and have had one consistently, which lets us make the sorts of investments into the Q2 quarter that we saw; we're able to truly invest for the future in a manner that few brands can. On top of that, they lack the economics to support that going forward and actually earn a return on it. Taking a quick glance at the balance sheet, we hold $109.4 million of cash and current financial assets. Our inventory levels are up. Inside the other assets section, we also carry prepayments on inventory that prepare us for the back half of the year. It prepares us for our new products, so we've put a lot of cash back in the form of inventories to fuel our growth. Now let's turn to the liabilities side. The warrant liabilities you see here represent the fair market valuation of the warrants sitting on the cap table, which we'll get to in a moment. We've got 2.36 million warrants carrying an $18 strike price. Beyond that, roughly 300,000 more sit at a few higher strike prices. Should the share price climb past $21.60 for 10 straight days, we hold a call option to pull those warrants in, and if that plays out, it would bring us an extra $42.5 million in cash. That figure essentially reflects the fair market value of the warrant liabilities recorded on our books. Trade payables make up most of the remaining liabilities. Moving on to the cap table. There's been plenty of confusion, I think, about what our cap table looks like and how fully diluted numbers shake out, so we've taken the step of presenting this clearly for everyone. What you're seeing is an outstanding share burden right now of 15.2 million shares. That breaks down as 13.6 million Class As plus roughly 1.6 million Class Bs. When you factor in the fully diluted picture, which accounts for grants not yet issued but available to be issued in the Class As, you'll notice that number rises to 14.5 million fully diluted.
If you look at the warrants further down, as I noted earlier, there are 2.36 million of them priced at $18, plus another 362,000 carrying strike prices of $24 and $32; those would bring in a meaningful amount of extra cash. Our fully diluted cap table would come to 19.2 million shares at that point. That figure captures everything grantable today across all our partners, and it should be viewed as the fully diluted burden; this reflects the change from December, and as you can see from our share buyback, we've managed to bring the count of Class A shares outstanding down to 13.6 million, compared with 15.3 million when the 2025 calendar year closed. Through that line, we've handed a substantial sum back to shareholders; then below that sit the warrant rolldowns. This shows the share flow since the year ended. We're genuinely happy to have returned some capital to shareholders in that manner; that wraps up the past as we move into discussing the financial statements. Turning now to unit economics and cohort math, which matters a great deal because what does that acquisition investment in Q2 actually deliver? Starting with the CAC chart we've touched on before. It helps frame what we meant about spend levels essentially doubling between Q1 and Q2, while you can see us doubling the average new customers we bring aboard. Then there's the July month, our biggest cohort ever, at a CAC that has fallen to $239. I should also note there's been no mix shift anywhere inside that July figure. The mix of quarterly versus monthlies matches what we saw previously, in terms of subscription duration and all of that. Nothing changed. So it's genuinely an apples to apples 21% gain in July compared with Q2; a huge amount of momentum as we head into Q3. Next we'll examine the return on those investments. This gives a nice picture of our quarterly vintages; some of you may have come across this very chart when the General Catalyst news broke; we showed it as the collective chart that General Catalyst and we had built together to underwrite our book of cohort vintages. Back then, looking at the pink line, the through Q1 figure, our gross profit to CAC and the dollars returned stood at $1.44. Jump ahead to now, and we've refreshed it just through that pink Q1 vintage group. It has climbed from $1.44 to $1.52, which is essentially the model. We picked up $0.08 on this return in only one month of return against the existing cohort business. Here's what the engine would anticipate: you'd see that figure keep climbing. Each dollar we've put into this operation across all Q1 cohorts has returned 1.52 times what we invested. Naturally, that metric will rise further as time passes. You'll notice the Q1 cohort is fairly sizable, the Q4 cohort is fairly sizable too, and these are cohorts that haven't had much time yet to mature. So that $1.52 represents only the start of where this operation will land over upcoming quarters; here's an excellent chart displaying panel data from one of our partners, Indagari. They handle credit card panel data across the U.S., so they account for somewhere between 6% and 8% of all online U.S. card transactions. Essentially, this covers the direct-to-consumer business for brands in the U.S. specifically, and 8% to 10% — sorry, 6% to 8% of the population. We compare quite favorably as a brand that's merely 20 months old against other major names in this space whom we clearly regard as pretty direct competitors. At month 20, our retention still sits at 14 on this chart. There's plenty of work ahead for us as a business. We remain quite young. We've got ample runway, yet this figure on its face is truly impressive. I mean, a brand that's accomplished what we have this early, and to have a month 20 retention figure at that point exceeding some excellent businesses in this space is no minor achievement, certainly. Then finally, turning to our subscriber base. This shows 140,000 active subscribers. You'll see we've grown pretty consistently across this entire period, but we've genuinely begun to speed up during the 26 periods, and have now hit 140,000. So these are active subscribers, and then near the bottom, you'll see the present base broken down by tenure. If you total some of those percentages, you'll find that 50% of our subscribers have stayed with the business for at least three months, which matters given that many of our subscribers, particularly from the standpoint of numerous cohorts joining the business, remain relatively immature and haven't been with the business that long. But half of our subscribers have already surpassed the three-month tenure, and this figure clearly will keep compounding into Q3 and the remainder of this year. So a genuinely strong subscriber base that powers this business as we move toward the next phases. Turning to the following view. This is where the cohort economics and the unit — sorry, the unit economics and the cohort math we just discussed will help steer us quite predictably through the next three to six quarters. If we simply let the current recurring revenue stream of this business play out, which is the basis for our guidance, it's fairly straightforward to anticipate where the coming quarters will end up. Our Q3 guidance points to $61.5 million to $62.5 million for IM8 revenue, or $63 million to $64 million at the Prenetics parent level. Based on Danny's guidance, that implies metrics of $220 million to $230 million across the full business, with an $81.2 million Q4, which would bring us to the top end of our guidance. We're also guiding toward a substantial EBITDA improvement, since the first half showed a $24.6 million EBITDA loss. For the second half, we anticipate that adjusted EBITDA loss narrowing to $8 million to $12 million. On our P&L, we expect this to take a few different forms; additional leverage should appear across most areas. Fixed operating costs ought to deliver solid leverage gains. We may see some further improvement on gross margin as we keep shifting toward the subscription duration of longer quarterlies and similar offerings, which carry more favorable margin; we also anticipate more leverage, particularly in our ambassador costs as a percent of sales, along with the acquisition spend line.
We anticipate that will likewise become more efficient when measured against sales. So there are numerous parts of the P&L pushing toward that adjusted EBITDA gain in the back half compared with the front half. I'd add that going forward, once we're a more mature operation, we'll quite probably present improved forms of guidance numbers across the various P&L lines, allowing us to truly dissect this. Still, we're highly confident in the guidance we've given and in a substantial lift on the adjusted EBITDA line, which, as you can observe on the revenue side, doesn't come at the expense of growth whatsoever. We're expecting a 38% rise in revenue for Q3 compared with Q2, plus a further sequential 31% gain in Q4; now let's turn to the following slide. This one is Q3 in particular. As stated, we're guiding to $61.5 million- $62.5 million for IM8 in particular, or $63 million- $64 million at the parent level. Momentum in Q3 looks excellent, so we're enthusiastic about this quarter both on the acquisition side and on the adjusted free cash flow side. With the General Catalyst financing now secured, July came in as a robust adjusted free cash flow positive stretch, and that pattern will persist going forward; so we're pretty thrilled about this quarter. Turning to Q4, this reflects the 81.2% implied revenue guidance for the year, assuming we reach the top end of our range. That would be 3x superior to the fourth quarter of 2025, which, as you'll observe, stood as our strongest quarter in 2025; it's a holiday quarter, and seasonally it's usually very strong. We achieved 59% sequential growth a year ago; at this point we're only guiding toward 31% sequential, so we view that figure as quite achievable. Furthermore, as Danny noted, these figures exclude the IM8 hydration launch in Q4, so all of that would represent upside to these numbers. Finally, Danny addressed this slide in passing. We anticipate finishing the 2026 calendar year at a $300 million annualized revenue run rate, equivalent to $25 million each month; after that we're guiding to no less than $400 million in 2027. I'd note that looking at the exit point of December 2025, which was just above $100 million, we've since delivered a year of $220 million- $230 million; so for us to claim we'll finish 2026 at a $300 million annualized revenue run rate and produce no less than $400 million the following year, that ratio is pretty attainable given what we just witnessed in this period. So we're very enthusiastic about the business. To bring it back to our past, present, future conversation, the past is genuinely strong in the shape of our financial statements. What we're seeing is that today's unit economics and cohorts are fueling tomorrow's expansion, while tomorrow is being shaped by our push into more markets, channels, and geographies. So our preference is to view the past as locked in, the present as steered and quantified, and the future — thanks to the $1 billion financing from General Catalyst and a solid balance sheet — as fully capitalized. Having said that, I'll hand things back to Danny so he can walk through more of what lies ahead.
Alright, thanks, Brian, for walking us through the P&L in that much detail. Now, before we move on to science, I truly want to extend a warm welcome to Caroline Levy. Caroline is with us on screen at this moment. Behind her, I can see the Golden Gate Bridge. That's the place where I was raised and where I spent many of my earliest years. Caroline — I've actually known Caroline for more than 2 years now. Our first encounter was in March 2022, in Los Angeles. I recall that initial meeting very well. At that point, I genuinely hoped Caroline would come onto the board, and this was before IM8. She politely turned me down, or rejected me, back then — her response was something like, "Hey, I need to observe a bit longer what you folks are doing, and see whether you can truly deliver on all the things you claim you will." Then, I'd say roughly 3, 4 months later, we connected once more. I'm extremely happy and honored to formally welcome Caroline. Yesterday, she came onto the Prenetics board, and also joined the auditing committee plus the governance and nominating committee. Since we've only just announced Caroline, it would be wonderful for her to take a few minutes. Caroline, you have so many choices when it comes to board seats, and for the last 30 years you've been on Wall Street as a fantastic consumer analyst. Perhaps in your own words, maybe just share with all of us the reason you chose to join us.
Thank you, Danny. Good morning, everyone. It's a real thrill for me to be joining the IM8 team; professional skepticism was my trade for over 30 years. In my analyst role, I was compensated for peering past the narrative, stress-testing the figures, the power of the brand, the rigor underpinning the expansion. Once you've done that at hundreds of consumer companies, large and small, your bar for what truly earns your respect gets set quite high. Three aspects of Prenetics and IM8 stood out to me. First, as Danny mentioned, we first met over two years ago, and what has struck me most is how well he gets things done. Throughout my career, I've listened to hundreds of CEOs lay out what they plan to build. The thing that counts, naturally, is what ends up getting accomplished, and Danny set out a clear ambition, and bit by bit, he has made good on it. I attach tremendous importance to that mix of ambition, focus, and follow-through. Second, the brand. My whole career was spent researching consumer brands, among them a few of the fastest-growing brands from the last decade. The bond IM8 has forged with consumers in a comparatively brief window is remarkable. Deep consumer loyalty is hard to establish. It's hard to maintain, and where it's authentic, it's incredibly valuable, and I sense there's something rather special in this case. Third, the part Danny wants me to take on. He didn't invite me onto the board merely to rubber-stamp his views. He invited me to apply the same rigor and readiness to pose tough questions that I've applied at companies all through my analyst career, and that matters a great deal to me. I'm coming onto the board genuinely enthusiastic about my duty to shareholders and to the company's long-term success. I'm absolutely delighted to be here, Danny. Back to you.
Thanks, Caroline. And once more, it's a real pleasure to have you join our board. I'm also thrilled to introduce Dr. Dawn Mussallem, who will be walking everyone through the science. That's honestly something we take great pride in — when I travel internationally, folks keep saying, "We genuinely appreciate the science. We appreciate all the principles you've stood for since the very beginning." Dr. Dawn has been involved with us since before the brand even launched. She holds the title of our founding scientific advisory board member. What's remarkable about Dawn is that when you encounter her face to face, she radiates hope and vitality. Her personal story is quite compelling too: while attending medical school, she received a stage 4 cancer diagnosis and was told she had three months to live. She made it through. Then in 2021 — roughly five years back — she had a heart transplant, a consequence of the cancer she'd faced more than 20 years earlier. On the one-year anniversary of receiving that heart, she became, I believe, the first woman globally to complete a full marathon. At the same time, she had been a founder at Mayo Clinic for its breast oncology center. Dr. Dawn, we truly appreciate you being with us since day one. Dawn will now walk us through the science, the history, and the reasons IM8 is so unique.
Thank you so much, Danny.
Dawn?
It makes me incredibly happy to be here and to mark this moment alongside IM8. Like you mentioned, after spending 20 years practicing medicine at Mayo Clinic, science sits at the core of everything I do. Other supplement companies had reached out to me many times, and honestly, I would simply erase every one of those messages, since Mayo Clinic would never have permitted me to get involved in anything like that — up until Danny sent me that email and gave me that call. What I recall from our very first conversation is that marketing never came up. All we discussed was the question of how to build the finest scientifically supported nutraceutical solution anywhere in the world. And that is precisely what we have accomplished. I had been waiting my whole professional life for a conversation like this, because before attending medical school, I actually worked as an exercise physiologist, with a particular focus on ergogenic aids, or nutraceuticals, capable of boosting a person's overall health span. During 2 decades at Mayo Clinic, however, I found myself completely absorbed in the sick care setting. I saw patients attempting to piece together their nutrition from shelves and bottles; they were taking 16 to 18 supplements, all of them inconsistent in quality, and a few of them causing harm. Certain patients would even arrive and end up admitted to the hospital because those supplements were genuinely injuring them while they tried to get healthy. The Daily Ultimate Essentials essentially takes the place of everything in those 16, 18 bottles people were consuming, packing over 90 ingredients into that delicious little daily sachet. If anyone listening on this call has yet to give it a try, consider this my invitation to go and try it, since the greatest investment available to you is in your own health. Let's begin there, with that IM8 Daily sachet, and it comes at a clinical dose. More than 74% of Americans have nutrient gaps, and closing those nutrient gaps and beyond is precisely what the Daily Ultimate Essentials is designed to accomplish. What I mentioned to you about safety sitting at the cornerstone of all our work — it isn't just a single hero product doing that; every individual SKU that IM8 brings out is NSF Certified for Sport, which means no banned substances are present, and beyond that it undergoes third-party batch testing, which means each ingredient listed on that label, along with its dose, is exactly what you receive. When you visit that IM8 website, transparency is there, so the actual certificate showing what each batch contains is available for you to see. Extremely, extremely important. On top of that, it screens for things capable of harming people, such as heavy metals and microplastics. No shortcuts were taken with the IM8 Daily Ultimate Essentials, and I understood that this was the product I wanted sitting at the foundation of what I helped create, working right alongside that amazing scientific advisory board. It isn't only me standing here. I speak for those other individuals you noticed on that stage, and together we make a fantastic group. Honestly, on the scientific advisory board, we discuss literally each and every day ways to improve what we do; so now, let me address how we demonstrate this. It all sounds wonderful. I know it can sound like I'm trying to sell you something, but the only reason for that is how strongly I believe in it. We ran a first study — 12 weeks, randomized, controlled — and here's what it demonstrated: 95% of the people in it said their energy was better and their vitality had improved. That was the main thing we were trying to achieve. We also got other feedback: an 85% improvement in gut health showed up; an 80% improvement in sleep ability showed up. People described themselves as more sharp. Greater clarity of thought was reported by 75% of them. They could tell something had changed. That's what brings people back again and again, and that's how we keep retention so high. We're going to maintain that same high bar for ourselves. That's the reason we're still doing research at what you might call my old stomping grounds — basically, Mayo Clinic is where I got virtually all of my training. Right now, there's a randomized controlled trial underway there involving healthcare workers. A hundred people are being signed up for it. The design is grounded in serious, rigorous science. Essentially, with the IM8 study at Mayo Clinic, which a former colleague of mine, Dr. George Pujalte is examining those 100 healthcare workers. These people work at the top research hospital globally, so when it comes to taking supplements, they are absolutely essential. Randomization is part of the design, meaning 50 of the 100 participants will receive IM8 without knowing it, while the remaining 50 get a placebo that's been matched to it, including in flavor. Actually, we went a bit out on a limb here, since the placebo contains a bit of beetroot extract too — so folks taking the placebo might notice improvement as well. For this study, anyone taking part needs to stop all other supplements for a four-week washout period first. Once the trial begins, they'll begin taking IM8 on day one. Lab work is done at the start as a baseline, then repeated when the study wraps up. The panels will measure various vitamins and minerals, markers of inflammation, and cardiometabolic indicators. Participants will also undergo functional assessments: a six-minute walk test paired with a VO2 equivalent calculation, body composition measured via InBody, grip strength testing, and, naturally, surveys on health-related quality of life. This kind of research carries a significant price tag. Research efforts in this area come with a price tag comparable to what drug makers typically spend. A great deal of credit is owed to Danny. What made that first conversation with him so significant to me — as a clinician, a research scientist, and a physician — is his willingness to fund the research and the science, and that genuinely matters. From that Mayo Clinic study, we expect to have data by Q2 of 2027, and it could arrive sooner. Now I'd like to walk you through the Longevity randomized controlled study. This is a fairly large trial with 180 subjects, randomly assigned to four distinct arms. In one of those arms, participants get a placebo, which means nothing at all. Another gets one dose of Longevity, a third gets two doses of Longevity, and the last gets the complete Beckham Stack, which consists of one sachet of Longevity plus one sachet of Daily Essentials. Our focus will be on inflammatory markers and metabolic markers; among the hallmarks of aging, these rank as two of the most significant. We're even aware that roughly 88%-92% of Americans essentially suffer from metabolic disease. This study matters enormously — it can teach us how to help Americans become healthier overall.
I am genuinely, truly thrilled about what we'll learn from these findings, and data from that trial should arrive in Q1 of 2027. Moving on to the Gut Health study: roughly 66% of people in America deal with GI problems, and more than 70 million of them have actually received diagnoses of digestive diseases. Enrollment for this trial sits at 135 people, and we will test three arms using varying dose responses. What makes this one stand out, though — since lots of supplement company trials rely purely on quality of life questionnaires, which is exactly the approach behind that initial study whose data I walked you through — is that we're going one level deeper here. We're genuinely performing gut microbiome sequencing via shotgun metagenomics. That's enormous, and it's incredibly thrilling, because the gut microbiome serves as our doorway toward bioindividualized optimization of essentially every function the body performs. So it's truly exciting to work alongside Suzanne Devkota and her team and discover what these findings reveal; yet we won't simply halt at that point. As Danny told you, between the close of this year and Q1, Q2, we'll launch some fresh, exciting items, beginning with the hydration one, which will include, well, I'm unsure whether I'm permitted to share specifics, but 2 forms of hydration. That way we can serve athletes along with folks who are simply at home and require hydration solutions, including patients and individuals facing complex health issues. Then comes the gummy. This is so thrilling since we can assist kids in becoming healthier, ensuring they get a tasty gummy containing beneficial fibers for their gut microbiome too, with no sugar and no artificial colorings. We will additionally get this item NSF certified and third-label tested. That guarantees none of those heavy metals will be present and that whatever appears on the label truly matches the dose that child receives. As a physician and as someone who is also a patient, my life has been owed to the world's finest medicine, and today we possess a nutraceutical answer created using equally rigorous methodology. I can assure you of this: IM8 is doing it right, and once more, keep in mind, the largest investment is the one you make in your health. Danny, handing it back to you.
Perfect. Thanks a lot, Dawn. I’ll close things out now—just one more minute. Let me pull together everything you’ve heard this morning onto a single page. Brian walked you through all the figures, Dr. Dawn walked you through the science. Here’s what it all comes to. There are 8 advantages, and each one makes the others stronger and better. The science: 3 trials underway, one of them at the Mayo Clinic. The brand: the one that gets passed from person to person. Then there’s General Catalyst, which once again underwrote $1 billion after spending months inside our cohorts, plus a subscription engine spanning 140,000 active subscribers and, once again, expanding very, very quickly. In July, we had our strongest month ever. An AI-native company, with 70 people each generating more than $3 million in revenue. A presence in 46 countries, and again, we launched with 31 countries on day one. Our biggest market is only 0.15% penetrated. Founders who own the outcome—my own capital, our athletes’ equity, all of it in the stock you hold. Now, any single one of those things a competitor can replicate. With money, they can buy certifications, and with money they can even buy trials, but those 8 together, compounding through the same subscribers, the same data, the same brand month after month for 20 months—that is something truly, truly rare that no one has managed to copy. That’s why we call ourselves IM8, and here’s what I want you to keep in mind as you move into your questions. Everything you saw today comes from only 2 products. The flywheel has only just started spinning, and that’s what makes me so excited to get up every day, and I’m so thankful for this opportunity and for what we’re able to accomplish because, again, we have tens of thousands of positive reviews around the world. I’ll finish there; we’re right on time, one hour. I know we’ve talked a lot. I think everyone on this stream has learned plenty. We aren’t finished yet, so I think the value of this format is that it lets everyone, especially our research analysts, ask us questions. Please don’t hesitate to ask Brian, me, or Dr. Dawn anything.
Hi, everyone. I appreciate you answering my questions. That was a really thorough summary, and I’m grateful for it. My first question is this: now that General Catalyst has essentially lifted the cash restriction on marketing, what’s the right way for us to think about spending during the second half of the year, particularly as we work to close the distance to the revised adjusted EBITDA loss?
Yeah, Brian, do you want to handle that?
Appreciate that, Ryan. As far as what we're expecting for the back half, the revenue percentage will probably land closer to what we saw in Q2, perhaps somewhat better than that figure, though the difference won't be significant. Our plan is to keep putting money into the business at about that same share of revenue. It likely won't be as low as what July came in at, and the reason is that we don't really anticipate that same level of customer acquisition efficiency from July carrying forward. My expectation is that you'll see somewhat more leverage on the marketing line, though not a great deal more relative to Q2.
All right, understood. With quarterly subscriptions taking up a bigger portion of the business and volumes still climbing, what's your view on where gross margins can sustainably land from this point onward? Clearly, we've just seen 65% gross margins for two quarters in a row. How ought we to frame that looking ahead as the mix shifts somewhat.
Yeah, fair question; when it comes to gross margin, the quarterly duration is certainly the more favorable one. Should the mix keep moving even more heavily toward quarterly, which you'd anticipate as those cohorts keep expanding and building in, my expectation is that at least a few points of extra margin would come simply from that element of mix improvement. Then there are economies of scale still ahead, and we haven't modeled, forecasted, or guided to those yet. But as this business keeps scaling, there's clear efficiency to capture through economies of scale, not only in the supply chain area and on the people and production side, but likewise in third-party logistics, postage, freight rates, and in the cost of product as well, working alongside our manufacturers to bring costs down by buying into more ingredients and capturing economies of scale that way; so my expectation is that this continues into 2027 as additional expansion at the gross margin level. So you've essentially got two parallel things occurring, and each one ought to be margin accretive for us.
Okay, understood. And finally, perhaps this one is for Dawn, since I am not sure we have ever talked before, and it is truly great to hear about the scientific underpinnings here. But as you all conduct some of these trials that are much more clinically focused — which clearly are extremely broad in scope — and from what I know, nobody else among supplement companies is doing this. What do you believe that delivers for the brand? Suppose you achieve positive results across all 3 of those. What kind of advantage do you think that gives all of you?
Well, these days our customers are getting far more informed. I appreciate that question, Ryan. Even more significantly, what we are observing is that doctors are treating this as the product they can rely on. It is available in Fullscript. I currently serve as Chief Medical Officer at Fountain Life, which ranks as the top longevity program globally. Basically every one of our physicians is now moving over members who had been consuming 16, 18 or more bottles. One time a patient came to Mayo Clinic with, quite literally, a suitcase full of supplements; having a single trusted supplement and a solution that can satisfy every one of these categories is such a relief. After that, you keep extending that pipeline forward by understanding where the demand lies with various items in development.
All right, understood. That's useful. Thanks, everyone.
As a matter of fact, Mayo Clinic actually carries this in its pharmacy; it's even available through the Mayo Clinic online store, where patients can buy it. So when the number one hospital in the world stocks it, that says a great deal.
Precisely.
To build on that, there's something we take a lot of pride in. A huge number of doctors are telling their patients to use this product, and that's genuinely uncommon in the supplement industry, correct? Take the New York Yankees physician, for instance — he's advising every one of their team players to use it, right? Jay Shetty learned about it from his own doctor. Aryna Sabalenka heard about it via her nutrition coach — that kind of thing almost never happens. And once more, whenever physicians give it their recommendation, they review the labels first, they check the NSF certifications, they examine everything prior to suggesting it. So that, I'd say, is something we feel a great deal of pride about.
Okay, that's wonderful to know. Thanks, both of you.
Hello there, Tom.
Excellent. Thanks a lot. To start, Danny and Brian, congratulations on the quarter and on the General Catalyst deal, and I appreciate you taking time this morning to explain things so clearly and thoughtfully. Dr. Dawn and Caroline, thank you for being on the call. There are three things I'd like to ask, and I'll take them one by one. Danny, broadly speaking, once you decide to move into a new category, what's the typical timeline until a product is actually on the market for consumers?
Honestly, we're quite deliberate and strategic whenever we introduce something new. That's because we also need to figure out whether we're capable of building the top product in that space. You saw those two slides I presented earlier. At this point, we've really focused on just two additional categories: hydration and gummies. One reason we picked hydration is that there are plenty of holes in what's currently available; competitors either load up on sugar, like Liquid I.V., or they load up on sodium. Once we noticed that, we asked ourselves, "Why not create something far superior?" Through conversations with Dawn, plus input from some of our SAB, we need to review all the clinical evidence so we can build a truly well-rounded product before it ever reaches manufacturing and testing, and so on. We also need to invest time in NSF certification on the clinical side. Going back to what you originally asked, I'd say our first thinking about hydration happened toward the end of last year. It will easily take 12 to 18 months, possibly more, before we actually launch a product. The upside is that we never hurry any new product to market, which explains why, again, across 20 months, you've seen just 2 SKUs from us, correct? Honestly, had we chosen to, we could have rolled out a dozen new SKUs. But I can assure you we wouldn't end up with a dozen strong SKUs, right? For us, what matters isn't how many SKUs exist, but rather each one we release — and we constantly push everyone: "Hey, run it through Claude, run it through ChatGPT. Is this the finest option versus everything else available?" I'd feel extremely sure, again, having personally tried around 50 different hydration products and roughly 30+ gummies, that when ours arrives, we'll offer the finest ingredients and the strongest certifications for them.
Great. For my follow-up, when you move into a brand-new category, how are we supposed to think about the choice between building something yourself and buying it?
At this moment, I'd say our approach is simply to build. Once again, we've managed to create an extremely powerful brand, and we're quite deliberate about which categories we explore. That said, whenever a strategic chance exists and we've got the money available for it, we'll certainly consider it. Still, what matters most to us today — and really the whole of my attention today — is product development itself, collaborating alongside the teams on clinical validation, and also keeping up our conversations with our SAB regarding what that pipeline might eventually resemble.
Great. And finally, Dr. Dawn and Caroline, since the two of you are here, I'd love to hear what you think about the growing consumer focus on health and wellness, and whether you see that as something spanning multiple generations rather than being limited to baby boomers.
It absolutely spans multiple generations. Caroline, would you like me to jump in and handle this one first? You're on mute. I'll go ahead and take it.
Danny, this is only my first day serving on your board. Would you like me to give that a try?
Yeah, feel free to. This is a general question, I think. Yeah, from-
It's a general question.
Health wise, yes. Probably.
Sure. I'd like to mention that I believe it was 25 years ago when I authored a report titled "The Absolute Risk of Obesity," where I discussed the issues surrounding sugar in the American diet and the danger it posed to stock valuations for Coke and Pepsi, and similar matters. For many, many years, I've been contemplating health and wellness. It was recognized as a trend a long time ago. We produced a futures report about it, and it seemed like we were pointing out something everyone already knew. What I've observed regarding trends is that they tend to progress gradually, getting adopted by early adapters, and then suddenly they hit an unbelievable acceleration curve, and I believe we've reached that stage. I think we haven't even begun to address what GLP-1s will do to people's health. I believe it will genuinely alter the sizing of American clothing, and furniture, and cause all kinds of repercussions, since people feel so much better, and the health outcomes are so much better; however, it also means we must consider bone health and other facets of our health more, and people don't simply want to live long lives, they want to live great lives, and we have a very powerful cohort among us older people. There are many of us, and we're not going quietly into the dark night; we are discovering new careers and want to contribute greatly to society. I think we are on the cusp of something truly enormous in health and wellness.
You're right, Caroline, and while the baby boomer group counts as one such segment, the most significant increase in prioritizing wellness actually comes from millennial and Gen Z wallets. Those more youthful demographics account for more than 41% of all wellness-related purchases — astonishing, really. They also represent the earliest cohort that isn't really consuming alcohol; their preference is mocktails. At our gatherings, we place heavy emphasis on bonding, feeling like you belong, and community. That comes through in every advertisement, which honestly gives me goosebumps to mention, yet what we have goes beyond a mere item. As you put it, Caroline, this truly is a bond involving health, wellness, and vitality, while carrying that idea of living life to the fullest. It's genuinely enjoyable to operate in this arena for essentially every age group, and these days that even means moving into children's products and protecting kids. Once more, safety comes first, something most businesses simply fail to consider properly. I'm genuinely proud to stand behind what we've made.
Excellent, and thanks to all of you for fielding my questions — I appreciate that.
Thanks.
Hi there, I appreciate you fielding my inquiry. To begin with, Danny and Brian, congratulations on the excellent quarter. It's wonderful to observe that ongoing momentum. I have a couple of questions regarding the competitive landscape. Could you kick things off by discussing a little about the way competition has changed across the past several months? Tied to that, whenever you're bringing on new customers, do those customers generally arrive from a rival offering or from newcomers to this category?
Yes.
Thanks.
Patrick, I believe that's something I can address. Some interesting stats from a competitive perspective have actually been published by us in the investor deck, and once more, this is independent third-party data. Even looking at just the last 20 months, since the brand launched, basically December 24, it is centralized. Looking at the landscape, we grew, obviously, close to 2,500%. During that same stretch of time, AG1 declined 36%. Grüns, I think, dropped roughly 50%. Over this period, Thorne rose 50%. From the top players, we have been taking quite significant market share, and rightfully so. In our view, the best product on the market is what we have. At the premium price point right now, too, that is key, I think, and this data was also published by us, the Incorta data, which is that on average-wise, at least across the whole supplement category, the highest average order value of any supplement brand is ours. Average-wise, it is $180. Looking at AG1, Thorne, about $80- $100 is where I think they are, and Grüns is like $50. What this means is that our customer clientele, and again, this is also published in this third-party data, is that above $150,000 or more is the household income of more than 50% of our current customers. If you think about that for a second, one of the reasons why after month 20, customers stay with us, I think, is that. Again, the product works, and really engaged customers are what we have. Yeah, so your question about the competitive landscape, I hope that answers it. Every month, we are growing. 47,000 new customers were added by us last month in July. From our data, another customer is where I believe 20%- 30% of new customers come from, and other ones, again, a lot of our customers, like Dr. Dawn mentions, five, six, seven different types of supplements may be taken by them, and for us wise, we have been able to condense and make it easy, where again, $200- $300 on a monthly basis does not have to be spent by you. On essentials, $9 a month is what you are spending, or on the Beckham Stack, $180. Helping people save money is something I think we have been able to do, in fact.
That's really useful. Thanks, Danny.
Appreciate you fielding questions, and congratulations on the quarter. From where I sit, the way acquisition costs have come down while spending has climbed is quite striking. Could you expand a bit on TikTok Shop and the social commerce initiatives you're running, and how you see them affecting CAC and AOV, plus how you weigh driving revenue through your own store versus elsewhere as those efforts grow?
Sure. Since the very beginning, IM8 has been built around direct to consumer, and most purchases happen on our own site. It's approximately 95%, with the other 5% coming from Amazon. That was intentional. Because when people buy through our own website in over 40 countries, we're able to deliver a far better experience for them. We also capture their email address, so whenever we release new products, it's easy for us to make an offer to our current customer base. So right now we're experimenting, or doing additional testing, on TikTok and AppLovin, but the bulk — I'd say 90%+ — of our customers complete purchases on our website. And we still see considerable growth potential from the DTC side, so I believe we'll keep expanding in that direction.
That's really useful. Thank you, Danny. I was glad as well to hear about the science and the research that's underway. Besides the point we just discussed — getting onto physicians' radars — could you speak to how you intend to use that science to build products or partnerships down the road, and tell us when results from those studies might come out?
Yeah, I'd say once more that from the very beginning science has sat at the center of what we're built on. Back when David Beckham and I first connected, roughly 3 years ago, we said to each other, "Hey, this has to be a brand rooted in science." That ties into, again, even that earlier question — this isn't some passing fad. Ultimately, I believe consumers want clarity on which ingredients are in a product. They want proof of results. They want independent lab verification. On our side, again, we post Eurofins results on our site. We also post NSF Contents Certified and NSF Certified for Sport. Relative to what you'd typically anticipate from a supplements company, we're pushing far past the standard. With the 2 trials currently in progress, one for Longevity and one for Gut, our expectation is that we'll have data from them by Q1. Mayo Clinic, since it's an academic institution, will probably need a bit more time, but our expectation there is roughly Q2 of Q3. As Dawn mentioned, again, these trials aren't cheap. They're multimillion-dollar studies that we've taken on. We genuinely see this becoming part of our moat when it comes to the science, though the truth is we can't know what those results will yield — still, we're confident, simply given how many customers we have, our scientific advisory board, and the caliber of ingredients in our product, that we'll generate some strong outcomes from it.
Thank you, I appreciate that. Setting aside the lengthy scientific track record, and given that Caroline has joined the board, I understand her experience includes beverages. I wondered whether you have any thinking regarding expanding into different form factors and possible retail sales, especially for the hydration product that's coming.
Yes. Excellent question. I'd say that's certainly a possibility, though my sense is that at this moment our priority is stick powders and stick packs, with IM8 hydration coming first. That said, I believe anything could happen down the road, correct? We aim to be extremely deliberate, and rushing into things isn't something we want to do. At present, what matters most to us is bringing out our 2 new categories in stick powders for IM8 hydration plus gummies, and following that, we'll evaluate.
Got it. I appreciate all that background.
Thanks. Is everyone able to hear me?
Yes. Hello, George.
All right. Hi, Danny. I appreciate you answering my questions and putting together this presentation for us today. I had a handful of things I wanted to ask you.
Of course.
To kick things off, I'd like to focus on how you performed in July. I'm curious whether you can share additional specifics regarding the factors behind the revenue acceleration and the better CAC. Was there a particular marketing channel, a partner, or something else that stands out? Also, I understand that your second half EBITDA guidance doesn't assume the July CAC trend will persist. Have you observed any type of normalization in August, or could you just share your thoughts on what August CAC has looked like so far?
Understood. Regarding the first question about July, clearly our CAC declined roughly 20% relative to Q2. During Q2, we spent heavily overall, almost twice what we did in Q1. I believe some of that carried over. To be honest, the brand — as I've said before, as I wrote in my shareholder letter and mentioned earlier — is becoming quite powerful. Internationally, whether I'm in the U.S., Europe, or Hong Kong, there's far more word of mouth, so paid channels aren't our only reliance. A great deal of organic word-of-mouth sharing is happening, and it's been really robust. I think we're also experiencing a halo effect from many of our ambassadors. Again, it isn't as though we have just one — we have an elite roster. In Q2, we brought on Giannis. Then came Inter Miami CF. And we also held many offline events, which is quite unusual for the supplement space since everyone operates online. Although we're 100% DTC online, we've taken part in 100+ events over the past 20 months. All these small elements combined, I believe, genuinely generate substantial word of mouth in recent months. Again, I'd say the same applies to Q2. In Q1, our CAC was $305. In Q2, our CAC was $301, so it dropped by $4 despite us doubling our spend; that almost never occurs. Again, you know my e-commerce background with Groupon, correct? I've never witnessed that. It only occurs when a brand grows stronger, right? That's what I think we're seeing here. Again, the wonderful part is that we'll be doing more with streaming, podcasts, YouTube, and all of those will be incremental new channels. As for August, it's still a little too soon, but continued momentum is still evident. However, commenting on the CAP is premature since I only have one full month of August data.
All right, that makes sense. That's useful. Are you able to hear me at this point?
Was I—I couldn't tell whether my— Danny Yeung: Yes, I'm able to.
All right, that sounds good. My follow-up is about the new items you're launching. From what I gather, these weren't included in the guidance you gave for either this year or the following one. I also get that these are very large segments and appear to fit well with the people who subscribe to you. I'm simply attempting to explore what kind of attachment might exist among the subscribers you currently have. Is there any survey information you can point to indicating that a certain share of our subscribers already purchase hydration, or anything else that would assist me as I attempt to estimate what revenue these launches might bring in?
Yes, so we've actually carried out — and that's a wonderful question, George — we've actually carried out surveys with the customers we already have, asking post-purchase survey questions about which main items they'd want IM8 to introduce. Once that survey was completed, the response we got was hydration along with gummies, at minimum from the people who buy from us. That's the reason we hold a strong belief that we'll do well in both of those segments, despite the fact that competition there is intense, since ultimately we also think we've managed to create a product that's far superior to whatever is currently offered on the market. As for attachment rates, the reason no guidance has been given is that, when it comes to a brand-new SKU, producing a reliable forecast is simply extremely hard. We'd rather not give out anything for which we lack a solid data set already. What I can share, based at minimum on our own customers, is that for hydration as well as gummies, over 20% of the customers we already have have requested this.
All right. Perhaps I can follow up on that. Do these lean more toward attachment items, or are they instead products with a reduced cost of acquiring customers and a smaller price point?
The two of those.
so at that point, with any luck, you're able to. The two of them are.
correct.
Okay.
So there would
And then-
It wouldn't come. Go ahead, sorry.
No. No, I stopped you there.
All right. Yeah, I'd describe it as having 2 parts, correct? It definitely isn't competing with what we already sell. Right, isn't that so? My view is that it will just be additive. Once again, there will be certain people who prefer a hydration item since, once again, they currently use a hydration offering from a different brand, correct? Our belief is that they could make the switch to what we offer. Around the globe, a sizable portion simply consume hydration, and we think we could bring them on, and after that we could also cross-sell and upsell them the standard IM8 Essentials and Longevity. I believe that plays to our benefit. Identically, in the same manner, this applies to the gummies too. Once again, we're considering gummies for kids, and then it isn't in competition with our existing offering, right? 20%, 30% of the customers we have now are parents already. Naturally, this might be a truly excellent item for kids, and once again, we could spot new customers arriving from the kids segment who in the end will move into our hero products of Essentials and Longevity.
Alright, that's my final question. Regarding your guided adjusted free cash flow along with adjusted EBITDA — are both of those adding back the General Catalyst funding?
Yes, they are. That's right, George.
Alright.
Alright, I think the size— Just to make that clear, on the cash flow statement, this will show up under financing cash. However, because it's actual money coming into the company and it's covering a big chunk of our P&L, we'll show an adjusted free cash flow view that treats it as operating cash flow plus what we get from General Catalyst, minus the repayment there.
Does your adjusted EBITDA guidance for the second half treat it the same way?
That cash from General Catalyst wouldn't affect EBITDA, apart from what sits below the line. In effect it would be interest, showing up as interest expense based on the repayment rate, yet the EBITDA guidance itself stays untouched — only cash flow would feel the effect.
Okay. Okay, thank you.
Yeah, thanks, George.
Appreciate it — I'll grab that one. So the opening question concerned retail versus the DTC model, correct? Well, as you're able to see, we've just wrapped up our strongest quarter to date, momentum carried into July, and every bit of our business is direct to consumer. When it comes to online growth, no deceleration is showing up whatsoever. Once more, on the vision side, my preference is to keep operations as streamlined and uncomplicated as we possibly can. Entering retail means dealing with an entirely different way of doing business, correct? Our belief is that we can scale, and scale effectively, for at least another 24 or 36 months with no retail footprint required. Building a really powerful online presence has been achievable for us. To repeat, across just the past 20 months, our Instagram following has reached 350,000. A single social ad we ran last year pulled 233 million views on Instagram, and producing numbers like that through retail simply isn't possible. To repeat, provided we keep enjoying such robust unit economics alongside payback periods that are so brief, nothing pushes us toward retail. The sole circumstance in which we'd pursue retail at this point — and I've made this point previously — would be if selling the brand were our goal. Selling the brand holds zero appeal for us, which means there's currently no justification for moving into retail.
And then when you look at the countries-
When it comes to the countries where we currently operate, 46 is the number today. China isn't among them, and neither is India, which you could call the two bigger nations. With China, clearly, we've got a fair amount of progress made, and that's probably going to call for another business model, probably with another team as well. My estimate would be 18 to 24 months away. As for India, we haven't looked into it so far. So those, more or less, are the sole nations we don't yet have coverage in at present.
No, that's a really good question. Once more, I'd say the space has been extremely hot over, let's say, the past 6 months. Huel was picked up by Danone, Unilever bought Grüns, and Thorne went to P&G. Altogether, I believe that comes to roughly $6 billion in acquisitions across that 6-month stretch. Yes, like I said a moment ago, the way we're constructing IM8 is not with a sale in mind; getting bought isn't what we're aiming for in building this business. When David and I launched this company, this brand, the thinking wasn't, "Hey, so how do we find an exit in the next 3 to 4 years?" Instead it was, "How do we create a generational health company across the coming 5, 10, 15 years?" That's the reason we put money into clinical trials, since those efforts require a great deal of time. If our intention were to sell the company, we'd never do this starting from day one. That said, we're a public company, and we also have an independent board. So should offers arrive, we're obligated to entertain them. Once more, my focus has always been on turning this into a generational health company. No matter what's going on out there, our job, my job along with Brian's, is to keep delivering quarter after quarter. As long as we keep doing that and the more data we accumulate — that's why we did this live stream, to assure the investors, the shareholders, because at this point I have 20 months of data. Six months back, 9 months back, I lacked that data, so there wasn't much we could show, but today we're in a position to do so. I think, once more, we'll keep delivering. I think those who've tracked our journey — again, I was just checking it yesterday, and it's pretty wild. Right now we're roughly a $350 million, $400 million company. Yet a year ago, we were around a $100 million company, and we were trading bombs. In just the past 12 months alone, for those who've been following us, we've already taken major leaps, and we'll keep delivering quarter after quarter. Again, I'm enjoying this so much. I think anyone who knows me is aware of that. It's a ton of work, but I don't refer to it as work since it's so enjoyable; we have a truly unique opportunity given all the momentum behind this brand. Yes. To address your question, I think, we'll simply deliver quarter after quarter, and I believe that will shut the gap eventually.
Okay, fantastic. Thanks so much, everybody. We've gone way past our slot, which I figure is a positive indicator just like it always is; the plan was 60 minutes, and here we are at 92 minutes. Once more, I appreciate all of you being here today, and for keeping up with us. I'd say this is a really, really thrilling moment. Don and Caroline, thank you for signing on. Stick with our journey. My guess is you two will be completely taken aback. Wonderful. Thanks.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Prenetics Global Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Prenetics Global Limited earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.